GTO ID | GTC0410 |
Trial ID |
NCT03397121
|
Disease |
Familial Hypercholesterolemia
|
Altered gene | PCSK9 |
Therapeutic/Target gene | Target gene |
Therapy | siRNA |
Treatment | ALN-PCSSC|Inclisiran|KJX839|Leqvio |
Location approved | EU, UK, Australia, Canada, Israel, US, Saudi Arabia, Japan, China |
Phase | Phase3 |
Recruitment status | Completed |
Title | Placebo-Controlled, Double-Blind, Randomized Trial to Evaluate the Effect of 300 mg of Inclisiran Sodium Given as Subcutaneous Injections in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH) and Elevated Low-Density Lipoprotein Cholesterol (LDL-C). |
Year | 2017 |
Country | Canada|Czechia|Denmark|Netherlands|South Africa|Spain|Sweden|United States |
Company sponsor | The Medicines Company |
Other ID(s) | MDCO-PCS-17-03|2017-002472-30 |